Cascades Reports Results for the Second Quarter of 2026

Cascades reported Q2 sales of CA$1,219m (+2.7% YoY) and net earnings of CA$21m (EPS CA$0.21 vs net loss CA$(0.03) YoY), alongside adjusted EBITDA (A) of CA$140m. Management expects annual run-rate adjusted EBITDA to exceed CA$600m in 2H26 (excluding tariff impact) after a June CA$50/ton packaging price increase, while net debt was CA$1,879m with leverage stable at 3.3x vs March. The key overhang is newly announced U.S. tariffs potentially applying a 50% rate to certain tissue and packaging exports, but management says mitigation should make the impact manageable and confirms confidence in the earnings trajectory.

Analysis

Cascades is showing real operating leverage, but the market should care more about the balance-sheet trajectory than the headline earnings beat. Stable leverage at 3.3x is acceptable, yet the delayed asset-sale timeline pushes meaningful de-risking into early 2027, which keeps equity duration high if the macro turns. That makes the name less of a clean operational recovery and more of a levered cash-flow story with policy overhang.

The tariff issue is not just a direct cost pass-through problem; it can break demand at the customer level. If U.S. buyers of imported tissue/packaging face a sharp landed-cost jump, the second-order effect is substitution toward domestic U.S. producers and, more importantly, order deferrals that hit volumes and mix across the supply chain. That argues for relative longs in U.S.-centric packaging names and caution on Canadian exporters exposed to cross-border freight and customs friction.

The consensus seems too comfortable with the word "manageable" because mitigation can offset direct tariff cost over months, while lost volume can show up immediately in orders. The near-term catalyst is management commentary on pricing realization versus volume erosion; the 6-18 month risk is that tariffs plus any oil-driven transport inflation force margin compression just as pricing resets. What would falsify the bearish read is clear evidence that H2 run-rate EBITDA stays above the stated target after tariffs, with no order weakness and no material drag from freight or input inflation.

Key Decisions for Investors

• Short CAS.TO into post-earnings strength on a 1-3 month horizon; thesis is that tariff uncertainty caps multiple expansion more than the Q2 beat can lift it. Risk/reward is attractive if the stock re-rates lower on weaker order commentary; stop if management quantifies immaterial direct tariff exposure and stable backlog.
• Pair trade: long IP / short CAS.TO for 1-3 months to express domestic share shift if U.S. tariffs are implemented as announced. Falsify the trade if CAS shows no volume loss and U.S. peers fail to gain pricing/share.
• Buy CAS.TO put spreads expiring after the next quarter if implied volatility does not already price in tariff risk. This is a cleaner expression than outright shorting if you want defined downside and protection against a sharp relief rally.
• Do not add to long CAS until the company demonstrates that pricing increases are sticking without volume deterioration. The key watch item is whether the H2 EBITDA guide is reaffirmed after the call and whether customers in tariff-exposed end markets are reducing production.